



Sheet 1 of 2

Form 1449*

** Eximinor

Atty. Docket No.: 600.491USECH CENTER 1600/2900

Serial No. 09/825,765

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant: Yumi Yokoyama et al.

Filing Date: April 4, 2001

Group: 1645

Filing Date

TT	0	क्रिक्ट के स्ट	DOCIDERNIS

**Rukkainor Initial	Document Mumber	Dato	Namo	Class	Subclass	Filing Date If Appropriate					
	· · · · · · · · · · · · · · · · · · ·										
≤ 50											
-334	5,767,071	06/16/1998	Palladino et al.	514	11	06/07/95					
-27H	5,792,845	08/11/1998	O'Reilly et al.	536	23.1	10/20/94					
-20H	5,854,205	12/29/1998	O'Reilly et al.	514	2	10/22/96					
FOREIGN PATENT DOCUMENTS											
**Rmaninor Initial	Document Mumber	Data	Country	Class	Subclass	Translation Yes No					
SIN	0896003	02/10/1999		C07K	14/75	100 100					
			•		,_						
OTHER DOCUMENTS											
**Examinor (Including Author, Title, Date, Pertinent Pages, Etc.) Initial											
COA	Arap, W., et al., "Cancer Treatment by Targeted Drug Delivery to Tumor										
Σ^{ν}	Vasculature	Vasculature in a Mouse Model", <u>Science</u> , <u>279</u> , pp. 377-380, (Jan. 16, 1998)									
				·							
SSTM		Boehm, T., et al., "Antiangiogenic therapy of experimental cancer does not									
		induce acquired drug resistance", Nature, 390, pp. 404-407, (Nov. 27, 1997)									
CDI	Brooks, P.C	., et al., "	Insulin-like Growth	Factor Rec	eptor Coo	perates With					
DJ4/	Clinical In	isseminatio		o", <u>Journal of</u>							
	Clinical in	<u>Clinical Investigation, 99 (6)</u> , pp. 1390-1398, (March 1997)									
95D1		Dawson, D.W., et al., "Pigment Epithelium-Derived Factor: A Potent Inhibitor									
247	of Angiogen	of Angiogenesis", <u>Science, 285</u> , pp. 245-248, (July 9, 1999)									
201	Dhanabal, M	Dhanabal, M., et al., "Endostatin Induces Endothelial Cell Apoptosis", The									
2011	Journal of	Journal of Biological Chemistry, 274 (17), pp. 11721-11726, (1999)									
Sil	Ferrara, N., et al., "Molecular and Biological Properties of the Vas Endothelial Growth Factor Family of Proteins", Endocrine Reviews, 13										
2041	18-32, (19	92)	ramily of Floceins	, BIIGOCITI	ne keview	$\frac{13}{1}$ (1), pp.					
			-11 11 11								
554	Folkman, J.	, "Anglogene	sis Inhibitors General	ated by Tu	mors", <u>Mo</u>	lecular					
	medicine,	pp. 120-122,	(1995)								
5JH	Folkman, J.	, "What is t	he Evidence That Tum	ors Are And	giogenesi	s Dependent?",					
<u> </u>	Journal of	Journal of the National Cancer Insititute, 82 (1), pp. 4-6, (Jan. 3, 1990)									
an 1	s by Distinct										
ZUM	alphav Inte	Friedlander, M., et al., "Definition of Two Angiogenic Pathways by Distinct alphav Integrins", Science, 270, pp. 1500-1502, (Dec. 1, 1995)									
			ovasculatization is a								
501	Export of b	FGF in the Mu	ltistep Development	nssociated of Fibrose	with a S	witch to the					
JU41	1095-1104.	(Sept. 20, 1	991)	or emprosa	. coma . , <u>c</u>	ETT, 00, Pb.					
			• •								

Examiner Date Considered *Substitute Disclosure Statement Form (PTO-1449

^{**}EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



COPY OF PAPERS ORIGINALLY FILED

Sheet 2 of 2

Form 1449*

Atty. Docket No.: 600.491US2

Serial No. 09/825,765

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)

Applicant: Yumi Yokoyama et al.

Group: 1645

OTHER DOCUMENTS

Filing Date: April 4, 2001

**Runninor Initial

(Including Author, Title, Date, Pertinent Pages, Etc.)

O'Reilly, M.S., et al., "Antiangiogenic Activity of the Cleaved Conformation of the Serpin Antithrombin", <u>Science</u>, <u>285</u>, pp. 1926-1928, (Sept. 17, 1999)

O'Reilly, M.S., et al., "Endostatin: An Endogenous Inhibitor of Antiogenesis and Tumor Growth", Cell, 88, pp. 277-285, (Jan. 24, 1997)

Yokoyama, Y., et al., "Genetic Modification of Human Endostatin: RGD-Motif Potentiates Anti-Tumor Activity", Proceedings of the American Association for Cancer Research, 41, Abstract No. 3112, p. 488, (March 2000)

RECENTER 1600/2900

Examiner

Date Considered

^{**}EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.